Children are not simply small adults; their bodies process medications differently. Before PREA, many drugs prescribed to children were not adequately tested in this population, leading to potential safety risks and ineffective dosing. PREA addresses this by requiring that clinical trials include pediatric participants, thereby ensuring that drugs are safe and effective for children.
